Edgewise Therapeutics, Inc.
- EWTX
- NASDAQ
- Biotechnology
- Musculoskeletal Therapeutics
- Small-Molecule Drugs
$38.15
Today +2.58%Quote Oct 19, 2026, 07:39 PM UTC
−20.77%over the last month
Max drawdown −22.7%From 1-month high −20.8%3 months −4.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
127
Market value
$4.10B
Quote Oct 19
Floor
$37.11
2.7% below price
Resistance
$38.14
Price is above this level
Price vs analyst targets
11 analysts
Lowest target
$36.00Highest target
$66.00
$36.00Highest target
$66.00
- Price $38.15
- Average target $53.10
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 39% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EWTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free